[
  {
    "ts": null,
    "headline": "S&P 500: Sick Puppies Dominate, But Here's A Trio Of A-List Stocks To Consider",
    "summary": "Discover why the S&P 500 conceals stock weaknesses & explore 3 healthcare picks from a data-driven analysis.",
    "url": "https://finnhub.io/api/news?id=20d39b5f35afe6cce3e909d2349678795903093ada48bbb6a9061a93ae5230c7",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755701752,
      "headline": "S&P 500: Sick Puppies Dominate, But Here's A Trio Of A-List Stocks To Consider",
      "id": 136439471,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1366605148/image_1366605148.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "Discover why the S&P 500 conceals stock weaknesses & explore 3 healthcare picks from a data-driven analysis.",
      "url": "https://finnhub.io/api/news?id=20d39b5f35afe6cce3e909d2349678795903093ada48bbb6a9061a93ae5230c7"
    }
  },
  {
    "ts": null,
    "headline": "Does Cobenfy Have the Potential to Become a Top Drug for BMY?",
    "summary": "Bristol Myers' Cobenfy, the first new schizophrenia treatment in decades, shows early sales momentum and strong pipeline expansion potential.",
    "url": "https://finnhub.io/api/news?id=c5a68468a846f104f35a0af88499def4e26c28d4cb90985c4ab028887ab577e4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755697920,
      "headline": "Does Cobenfy Have the Potential to Become a Top Drug for BMY?",
      "id": 136437475,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Bristol Myers' Cobenfy, the first new schizophrenia treatment in decades, shows early sales momentum and strong pipeline expansion potential.",
      "url": "https://finnhub.io/api/news?id=c5a68468a846f104f35a0af88499def4e26c28d4cb90985c4ab028887ab577e4"
    }
  },
  {
    "ts": null,
    "headline": "Supply-Chain Tech Firm Overhaul Raises $105 Million",
    "summary": "Supply-chain risk management company Overhaul raised $105 million as it seeks to capitalize on growing demand for freight tracking services, in part to combat cargo theft.  The Series C funding round was led by Springcoast Partners and Edison Partners, with additional debt financing from MidCap Financial.  Austin, Texas-based Overhaul will use the funding to invest in artificial-intelligence technology and make acquisitions.",
    "url": "https://finnhub.io/api/news?id=9734673f80d80c9d4be8451651bf3d696c4f609b553ddbb180731a93d9e0d754",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755691200,
      "headline": "Supply-Chain Tech Firm Overhaul Raises $105 Million",
      "id": 136437243,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Supply-chain risk management company Overhaul raised $105 million as it seeks to capitalize on growing demand for freight tracking services, in part to combat cargo theft.  The Series C funding round was led by Springcoast Partners and Edison Partners, with additional debt financing from MidCap Financial.  Austin, Texas-based Overhaul will use the funding to invest in artificial-intelligence technology and make acquisitions.",
      "url": "https://finnhub.io/api/news?id=9734673f80d80c9d4be8451651bf3d696c4f609b553ddbb180731a93d9e0d754"
    }
  },
  {
    "ts": null,
    "headline": "FDA awards breakthrough therapy status to BMS and SystImmune’s NSCLC drug",
    "summary": "NSCLC represents 80% of lung cancer cases and is the leading cause of cancer-related mortality globally.",
    "url": "https://finnhub.io/api/news?id=898d34d6f854f928634f53576d7435aa24b320411635861b8ef676ac477555d9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755688502,
      "headline": "FDA awards breakthrough therapy status to BMS and SystImmune’s NSCLC drug",
      "id": 136437751,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "NSCLC represents 80% of lung cancer cases and is the leading cause of cancer-related mortality globally.",
      "url": "https://finnhub.io/api/news?id=898d34d6f854f928634f53576d7435aa24b320411635861b8ef676ac477555d9"
    }
  },
  {
    "ts": null,
    "headline": "Pharmaceuticals Industry Analysis:  Eli Lilly Tops My Tier Two",
    "summary": "Tier-two pharma picks show solid fundamentals, but Eli Lilly (LLY) stock stands out for its growth potential. Read here for an analysis.",
    "url": "https://finnhub.io/api/news?id=c3907d374789a13bcc0a4f263b16cfc191ed507efec252bde9661f419a70bf5a",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755663369,
      "headline": "Pharmaceuticals Industry Analysis:  Eli Lilly Tops My Tier Two",
      "id": 136435370,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1291269124/image_1291269124.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "Tier-two pharma picks show solid fundamentals, but Eli Lilly (LLY) stock stands out for its growth potential. Read here for an analysis.",
      "url": "https://finnhub.io/api/news?id=c3907d374789a13bcc0a4f263b16cfc191ed507efec252bde9661f419a70bf5a"
    }
  }
]